<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36894193</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e002881</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2022-002881</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Antiphospholipid syndrome (APS) is an autoimmune disease characterised by thrombosis (arterial, venous or small vessel) or obstetrical events and persistent antiphospholipid antibodies (aPL), according to the Sydney classification criteria. Many studies have performed cluster analyses among patients with primary APS and associated autoimmune disease, but none has focused solely on primary APS. We aimed to perform a cluster analysis among patients with primary APS and asymptomatic aPL carriers without any autoimmune disease, to assess prognostic value.</AbstractText><AbstractText Label="METHODS">In this multicentre French cohort study, we included all patients with persistent APS antibodies (Sydney criteria) measured between January 2012 and January 2019. We excluded all patients with systemic lupus erythematosus or other systemic autoimmune diseases. We performed hierarchical cluster analysis on the factor analysis of mixed data coordinates results with baseline patient characteristics to generate clusters.</AbstractText><AbstractText Label="RESULTS">We identified four clusters: cluster 1, comprising 'asymptomatic aPL carriers', with low risk of events during follow-up; cluster 2, the 'male thrombotic phenotype', with older patients and more venous thromboembolic events; cluster 3, the 'female obstetrical phenotype', with obstetrical and thrombotic events; and cluster 4, 'high-risk APS', which included younger patients with more frequent triple positivity, antinuclear antibodies, non-criteria manifestations and arterial events. Regarding survival analyses, asymptomatic aPL carriers relapsed less frequently than the others, but no other differences in terms of relapse rates or deaths were found between clusters.</AbstractText><AbstractText Label="CONCLUSIONS">We identified four clusters among patients with primary APS, one of which was 'high-risk APS'. Clustering-based treatment strategies should be explored in future prospective studies.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guedon</LastName><ForeName>Alexis F</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0002-4571-6219</Identifier><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;,Service de M&#xe9;decine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), H&#xf4;pital Saint-Antoine, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricard</LastName><ForeName>Laure</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;,Service de M&#xe9;decine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), H&#xf4;pital Saint-Antoine, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laurent</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;,Service de M&#xe9;decine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), H&#xf4;pital Saint-Antoine, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Moreuil</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Interne, CHRU de Brest, Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urbanski</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Interne et Immunologie Clinique, Centre Hospitalier Universitaire d'Angers, Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deriaz</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Interne, CHRU et universit&#xe9; de Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerotziafas</LastName><ForeName>Grigorios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service de H&#xe9;mostase et H&#xe9;matologie Biologique, H&#xf4;pital Tenon, AP-HP, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elalamy</LastName><ForeName>Ismail</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Service de H&#xe9;mostase et H&#xe9;matologie Biologique, H&#xf4;pital Tenon, AP-HP, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Audemard</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Interne, CHRU et universit&#xe9; de Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chasset</LastName><ForeName>Francois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Service de Dermatologie et V&#xe9;n&#xe9;rologie, H&#xf4;pital Tenon, AP-HP, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alamowitch</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service des Urgences C&#xe9;r&#xe9;bro-Vasculaires, H&#xf4;pital Piti&#xe9;-Salp&#xe9;tri&#xe8;re, AP-HP, Centre de Recherche de Saint Antoine, INSERM, UMRS 938, Sorbonne Universit&#xe9; Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sellam</LastName><ForeName>J&#xe9;r&#xe9;mie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Service de Rhumatologie, CRSA INSERM, UMRS 938, H&#xf4;pital Saint-Antoine, AP-HP, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boffa</LastName><ForeName>Jean Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Service de N&#xe9;phrologie, H&#xf4;pital Tenon, AP-HP, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ariel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de Cardiologie, H&#xf4;pital Saint-Antoine, AP-HP, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahl</LastName><ForeName>Cl&#xe9;mentine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Service d'h&#xe9;matologie biologique, AP-HP, H&#xf4;pital Saint-Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abisror</LastName><ForeName>Noemie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;,Service de M&#xe9;decine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), H&#xf4;pital Saint-Antoine, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maillot</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Interne, CHRU et universit&#xe9; de Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fain</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;,Service de M&#xe9;decine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), H&#xf4;pital Saint-Antoine, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mekinian</LastName><ForeName>Ars&#xe8;ne</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2849-3049</Identifier><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;,Service de M&#xe9;decine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), H&#xf4;pital Saint-Antoine, AP-HP, Paris, France arsene.mekinian@aphp.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiphospholipid Syndrome</Keyword><Keyword MajorTopicYN="N">Autoimmune Diseases</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword></KeywordList><CoiStatement>Competing interests: SA received fees from AstraZeneca, Bayer and BMS-Pfizer for consultancy and lectures. All other authors declared no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>9</Day><Hour>20</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36894193</ArticleId><ArticleId IdType="pmc">PMC10008476</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2022-002881</ArticleId><ArticleId IdType="pii">rmdopen-2022-002881</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Miyakis S, Lockshin MD, Atsumi T, et al. . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295&#x2013;306. 10.1111/j.1538-7836.2006.01753.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 2018;378:2010&#x2013;21. 10.1056/NEJMra1705454</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1705454</ArticleId><ArticleId IdType="pubmed">29791828</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Puerta JA, Mart&#xed;n H, Amigo M-C, et al. . Long-Term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 2005;84:225&#x2013;30. 10.1097/01.md.0000172074.53583.ea</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000172074.53583.ea</ArticleId><ArticleId IdType="pubmed">16010207</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu&#xe9;don AF, Catano J, Ricard L, et al. . Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study. Arthritis Res Ther 2022;24:33. 10.1186/s13075-022-02726-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-022-02726-9</ArticleId><ArticleId IdType="pmc">PMC8788111</ArticleId><ArticleId IdType="pubmed">35078523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricard L, Laurent C, Papo M, et al. . Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: a multicenter retrospective study. Joint Bone Spine 2022;89:105297. 10.1016/j.jbspin.2021.105297</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2021.105297</ArticleId><ArticleId IdType="pubmed">34656751</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelnik CM, Urbanski G, Drumez E, et al. . Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus 2017;26:163&#x2013;9. 10.1177/0961203316657433</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316657433</ArticleId><ArticleId IdType="pubmed">27432808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata Y, Fujieda Y, Sugawara M, et al. . Morbidity and mortality in antiphospholipid syndrome based on cluster analysis: a 10-year longitudinal cohort study. Rheumatology (Oxford) 2021;60:1331&#x2013;7. 10.1093/rheumatology/keaa542</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa542</ArticleId><ArticleId IdType="pubmed">32944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Radin M, Cecchi I, et al. . Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients. Rheumatology (Oxford) 2021;60:1106&#x2013;13. 10.1093/rheumatology/kez596</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez596</ArticleId><ArticleId IdType="pubmed">31840749</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuily S, Clerc-Urm&#xe8;s I, Bauman C, et al. . Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS action registry. Lupus 2020:961203320940776. 10.1177/0961203320940776</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320940776</ArticleId><ArticleId IdType="pmc">PMC8216235</ArticleId><ArticleId IdType="pubmed">32703117</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennig C. Cluster-wise assessment of cluster stability. Computational Statistics &amp; Data Analysis 2007;52:258&#x2013;71. 10.1016/j.csda.2006.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csda.2006.11.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R, Serrano R, Pons-Estel GJ, et al. . Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015;74:1011&#x2013;8. 10.1136/annrheumdis-2013-204838</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204838</ArticleId><ArticleId IdType="pubmed">24464962</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Andreoli L, Scanzi F, et al. . The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun 2017;76:10&#x2013;20. 10.1016/j.jaut.2016.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2016.10.004</ArticleId><ArticleId IdType="pubmed">27776934</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Sanchez C, Barbarroja N, Messineo S, et al. . Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis 2015;74:1441&#x2013;9. 10.1136/annrheumdis-2013-204600</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204600</ArticleId><ArticleId IdType="pubmed">24618261</ArticleId></ArticleIdList></Reference><Reference><Citation>Natorska J, Celi&#x144;ska-L&#xf6;wenhoff M, Undas AI. High prevalence of antinuclear antibodies in patients following venous thromboembolism. Adv Clin Exp Med 2018;27:827&#x2013;32. 10.17219/acem/78361</Citation><ArticleIdList><ArticleId IdType="doi">10.17219/acem/78361</ArticleId><ArticleId IdType="pubmed">29877639</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V, Biasiolo A, Pegoraro C, et al. . Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005;93:1147&#x2013;52. 10.1160/TH04-12-0839</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH04-12-0839</ArticleId><ArticleId IdType="pubmed">15968401</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V, Ruffatti A, Legnani C, et al. . Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010;8:237&#x2013;42. 10.1111/j.1538-7836.2009.03674.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2009.03674.x</ArticleId><ArticleId IdType="pubmed">19874470</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V, Ruffatti A, Legnani C, et al. . Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011;118:4714&#x2013;8. 10.1182/blood-2011-03-340232</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-03-340232</ArticleId><ArticleId IdType="pubmed">21765019</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires da Rosa G, Bettencourt P, Rodr&#xed;guez-Pint&#xf3; I, et al. . &#x201c; Non-criteria&#x201d; antiphospholipid syndrome: a nomenclature proposal. Autoimmun Rev 2020;19:102689. 10.1016/j.autrev.2020.102689</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102689</ArticleId><ArticleId IdType="pubmed">33223008</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraley C, Raftery AE. How many clusters? which clustering method? answers via model-based cluster analysis. The Computer Journal 1998;41:578&#x2013;88. 10.1093/comjnl/41.8.578</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/comjnl/41.8.578</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>